Piper Jaffray Cos. lowered shares of uniQure NV (NASDAQ:QURE) from an overweight rating to a neutral rating in a research note published on Tuesday morning.

Other analysts have also recently issued reports about the stock. Jefferies Group set a $28.00 price objective on shares of uniQure NV and gave the stock a buy rating in a research note on Thursday, July 28th. Chardan Capital set a $35.00 target price on shares of uniQure NV and gave the stock a buy rating in a research report on Thursday, July 28th. Cowen and Company restated a buy rating on shares of uniQure NV in a research report on Thursday, July 28th. HC Wainwright started coverage on shares of uniQure NV in a research report on Thursday, August 4th. They set a buy rating and a $21.00 target price for the company. Finally, Zacks Investment Research upgraded shares of uniQure NV from a sell rating to a hold rating in a research report on Wednesday, September 21st. One equities research analyst has rated the stock with a hold rating and ten have issued a buy rating to the stock. The stock presently has an average rating of Buy and an average target price of $24.70.

Analyst Recommendations for uniQure NV (NASDAQ:QURE)

uniQure NV (NASDAQ:QURE) opened at 7.07 on Tuesday. uniQure NV has a 52-week low of $6.63 and a 52-week high of $22.79. The firm has a 50 day moving average of $7.29 and a 200-day moving average of $8.77. The stock’s market cap is $177.66 million.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Baker BROS. Advisors LP bought a new position in uniQure NV during the third quarter valued at approximately $1,760,000. BlackRock Institutional Trust Company N.A. increased its position in uniQure NV by 200.3% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 70,322 shares of the company’s stock worth $538,000 after buying an additional 46,905 shares during the period. JPMorgan Chase & Co. increased its position in uniQure NV by 121.1% in the third quarter. JPMorgan Chase & Co. now owns 31,340 shares of the company’s stock worth $240,000 after buying an additional 17,166 shares during the period. Capital Fund Management S.A. acquired a new position in uniQure NV during the third quarter worth approximately $111,000. Finally, Point72 Asset Management L.P. increased its position in uniQure NV by 105.7% in the second quarter. Point72 Asset Management L.P. now owns 562,447 shares of the company’s stock worth $4,145,000 after buying an additional 288,982 shares during the period. 31.68% of the stock is currently owned by institutional investors.

About uniQure NV

uniQure N.V. is engaged in the field of gene therapy. The Company is engaged in the discovery, development and commercialization of gene therapies. It has a technology platform that uses as the basis for collaborative product candidates across approximately three therapeutic focus areas, such as Liver/Metabolic Disease, Central Nervous System (CNS) Disease and Cardiovascular Disease.

5 Day Chart for NASDAQ:QURE

Receive News & Stock Ratings for uniQure NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure NV and related stocks with our FREE daily email newsletter.